Drug name - Dayvigo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(8 years from now)

CN103153963A EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

CN103153963B EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

IN201303338P1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

IN387588B EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350A4 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350A1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350B1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia Oct, 2035

(13 years from now)

Drugs and Companies using LEMBOREXANT ingredient

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.